Assessing germline variants in GBM patients’ blood by sequencing and determining the transcript levels of Fc-γRIII in the tumor will be immediate steps necessary to investigate the relevance of Fc-γR polymorphisms with anti–CTLA-4 therapies in GBM. The gene discussed is FCGR2A; the disease is glioblastoma.